GSK has entered a definitive agreement to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for inflammatory and immunologic diseases. The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody, currently in Phase IIb clinical development for prophylactic protection against food allergens. Under the terms of the agreement, GSK will pay RAPT […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!